Therapeutic progress II: treatment of psoriasis

Lewis, H.

doi:10.1111/j.1365-2710.1994.tb00678.x

Cited by 13 publications

(6 citation statements)

References 41 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When present in an appreciable amount, coumarin may have an aspi rinlike effect of prolonging the blood coagulation time (Egan et al, 1990) and may play a role in photosensiti zation reactions (Lewis, 1994;McNeely and Goa, 1998). It is present in certain varieties of cinnamon, which is also used for glucose balance.…”

Section: Coumarinmentioning

confidence: 99%

Fenugreek

Garg¹

2016

Nutraceuticals

View full text Add to dashboard Cite

Section: Coumarinmentioning

confidence: 99%

Fenugreek

Garg¹

2016

Nutraceuticals

View full text Add to dashboard Cite

“…Patients with severe, refractory lesions should be referred to ultraviolet light B (UVB) or oral psoralen with ultraviolet A therapy (PUVA). Systemic therapy with retinoids, cyclosporine or cytotoxic drugs may be offered as alternatives but require supervision by those experienced with their use (Lewis, 1994 opdons for psoriasis and their associated side effects are summarized in Table 2. Fortunately.…”

Section: Treatmenrmentioning

confidence: 99%

Psoriasis: pathophysiology and oral manifestations

et al. 1996

View full text Add to dashboard Cite

Psoriasis is a chronic, remitting and relapsing inflammatory skin disorder with a strong genetic predisposition. Psoriasis affects 1–3% of the world's population in their early lives representing a disabling condition with significant social and economic impact. Despite a great deal of research on the etiology and tissue destruction mechanisms, the disease is not well understood. The purpose of this paper is to provide current information from the literature with a special focus on oral manifestations. The major signs and symptoms presented in the oral environment of a psoriasis patient may include geographic tongue, fissure tongue, gingival and/or mucosal lesions. Inflammatory temporomandibular joint lesions have been reported in less than 5% of psoriasis patients. Multiple treatment strategies, be they topical or systemic, have been applied to these patients for symptom relief but not for cure.

show abstract

“…None of these therapies cure psoriasis; [56][57][58] therefore treatment is aimed at suppressing the disease and restricting its severity and extent to within tolerable limits. None of these therapies cure psoriasis; [56][57][58] therefore treatment is aimed at suppressing the disease and restricting its severity and extent to within tolerable limits.…”

Section: Therapeutic Efficacy In Psoriasismentioning

confidence: 99%

Calcipotriol

Lea¹,

Goa²

1996

Clin. Immunother.

View full text Add to dashboard Cite

SynopsisCalcipotriol (calcipotriene) is a vitamin D3 analogue which inhibits cell proliferation. enhances cell differentiation and appears to influence immunological fa ctors which may playa role in the origins o/psoriasis. In patients with chronic Calcipotriol: A Review Overview of Pharmacological Properties Therapeutic Efficacy plaque psoriasis, twice-daily topical calcipotriol 50 flglg is more effective than unmedicated vehicle, betamethasone (betamethasone valerate), fiuocinonide, dithranol (anthralin) and coal tar in patients with nonscalp psoriasis; however; patients with scalp psoriasis respond better to betamethasone than calcipotriol. In the treatment of patients with severe psoriasis, calcipotriol used together with cyclosporin or psoralen ultraviolet A yields superior results to those achieved with either regimen alone. The efficacy of calcipotriol demonstrated in short term trials is sustained in noncomparative studies of up to 1 year in duration. Data from several clinical trials involving nearly 2000 patients show that calcipotriol is well tolerated, the most common adverse events being mild and transient irritation of lesions or peri Ie siona I skin which occur in 15.1 to 25.8% of patients. At recommended dosages hypercalcaemia and hypercalciuria are very rare. Calcipotriol is better tolerated than short-contact dithranol, but causes more adverse events than betamethasone particularly in patients with scalp psoriasis. 231

show abstract

Therapeutic progress II: treatment of psoriasis

Cited by 13 publications

References 41 publications

Fenugreek

Fenugreek

Psoriasis: pathophysiology and oral manifestations

Calcipotriol

Contact Info

Product

Resources

About